OREANDA-NEWS. Nippon Boehringer Ingelheim Co., Ltd. (Head Office:Tokyo; President and Representative Director: Yoshiaki Aono; hereinafter “Nippon Boehringer Ingelheim”) and Astellas Pharma Inc. (Head Office:Tokyo; President and CEO: Yoshihiko Hatanaka; hereinafter “Astellas”) have decided to extend the agreement pertaining to the sale and co-promotion in Japan for telmisartan (Micardis® family). The term of the agreement, which runs to December 31, 2016, will be extended to March  31, 2018.  

The Micardis® family includes “Micardis® Tablets 20 mg/40 mg/80mg, ”a long-acting angiotensin II receptor antagonist (generic name:telmisartan), “Micamlo® Combination Tablets AP/BP”, a combination drug of telmisartan and long-acting calcium channel blocker amlodipine besylate, and “Micombi® Combination Tablets AP/BP”, a combination drug of telmisartan and thiazide diuretic hydrochlorothiazide, and also includes a combination drug for which the approval application has been submitted in Japan, featuring three ingredients, telmisartan, long-acting calcium channel blocker amlodipine besylate and thiazide diuretic hydrochlorothiazide.